Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
BSPM's Cash to Debt is ranked higher than
96% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. BSPM: No Debt )
BSPM' s 10-Year Cash to Debt Range
Min: 1.26   Max: No Debt
Current: No Debt

Equity to Asset 0.91
BSPM's Equity to Asset is ranked higher than
95% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. BSPM: 0.91 )
BSPM' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.96
Current: 0.91

0.79
0.96
Interest Coverage 1.38
BSPM's Interest Coverage is ranked lower than
56% of the 431 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. BSPM: 1.38 )
BSPM' s 10-Year Interest Coverage Range
Min: 1.38   Max: 9999.99
Current: 1.38

1.38
9999.99
F-Score: 6
Z-Score: 3.56
M-Score: -2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.96
BSPM's Operating margin (%) is ranked higher than
58% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. BSPM: 0.96 )
BSPM' s 10-Year Operating margin (%) Range
Min: -44.17   Max: 30.5
Current: 0.96

-44.17
30.5
Net-margin (%) 1.53
BSPM's Net-margin (%) is ranked higher than
60% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. BSPM: 1.53 )
BSPM' s 10-Year Net-margin (%) Range
Min: -40.55   Max: 24.95
Current: 1.53

-40.55
24.95
ROE (%) 1.29
BSPM's ROE (%) is ranked higher than
59% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. BSPM: 1.29 )
BSPM' s 10-Year ROE (%) Range
Min: -34.61   Max: 28.75
Current: 1.29

-34.61
28.75
ROA (%) 1.20
BSPM's ROA (%) is ranked higher than
62% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. BSPM: 1.20 )
BSPM' s 10-Year ROA (%) Range
Min: -28.37   Max: 25.53
Current: 1.2

-28.37
25.53
ROC (Joel Greenblatt) (%) 1.51
BSPM's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.90 vs. BSPM: 1.51 )
BSPM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -69.15   Max: 82.81
Current: 1.51

-69.15
82.81
Revenue Growth (%) -23.60
BSPM's Revenue Growth (%) is ranked lower than
52% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. BSPM: -23.60 )
BSPM' s 10-Year Revenue Growth (%) Range
Min: -23.6   Max: 56.6
Current: -23.6

-23.6
56.6
EBITDA Growth (%) -45.30
BSPM's EBITDA Growth (%) is ranked lower than
53% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. BSPM: -45.30 )
BSPM' s 10-Year EBITDA Growth (%) Range
Min: -45.3   Max: 50
Current: -45.3

-45.3
50
EPS Growth (%) -68.40
BSPM's EPS Growth (%) is ranked lower than
53% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. BSPM: -68.40 )
BSPM' s 10-Year EPS Growth (%) Range
Min: -68.4   Max: 49.4
Current: -68.4

-68.4
49.4
» BSPM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

BSPM Guru Trades in Q2 2013

Jim Simons 188,670 sh (+4.31%)
» More
Q3 2013

BSPM Guru Trades in Q3 2013

Jim Simons 196,370 sh (+4.08%)
» More
Q4 2013

BSPM Guru Trades in Q4 2013

Jim Simons 320,142 sh (+63.03%)
» More
Q1 2014

BSPM Guru Trades in Q1 2014

Jim Simons 541,070 sh (+69.01%)
» More
» Details

Insider Trades

Latest Guru Trades with BSPM



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 71.60
BSPM's P/E(ttm) is ranked higher than
68% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.50 vs. BSPM: 71.60 )
BSPM' s 10-Year P/E(ttm) Range
Min: 1.03   Max: 156.32
Current: 71.6

1.03
156.32
P/B 0.30
BSPM's P/B is ranked higher than
99% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. BSPM: 0.30 )
BSPM' s 10-Year P/B Range
Min: 0.11   Max: 3.04
Current: 0.3

0.11
3.04
P/S 0.36
BSPM's P/S is ranked higher than
98% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. BSPM: 0.36 )
BSPM' s 10-Year P/S Range
Min: 0.13   Max: 2.2
Current: 0.36

0.13
2.2
PFCF 2.40
BSPM's PFCF is ranked higher than
100% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BSPM: 2.40 )
BSPM' s 10-Year PFCF Range
Min: 0.54   Max: 28.25
Current: 2.4

0.54
28.25
EV-to-EBIT -12.45
BSPM's EV-to-EBIT is ranked higher than
53% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.97 vs. BSPM: -12.45 )
BSPM' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 97.5
Current: -12.45

0.1
97.5
Shiller P/E 2.80
BSPM's Shiller P/E is ranked higher than
99% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BSPM: 2.80 )
BSPM' s 10-Year Shiller P/E Range
Min: 1.15   Max: 6.06
Current: 2.8

1.15
6.06
Current Ratio 6.06
BSPM's Current Ratio is ranked higher than
89% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. BSPM: 6.06 )
BSPM' s 10-Year Current Ratio Range
Min: 1.68   Max: 19.49
Current: 6.06

1.68
19.49
Quick Ratio 5.96
BSPM's Quick Ratio is ranked higher than
91% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.67 vs. BSPM: 5.96 )
BSPM' s 10-Year Quick Ratio Range
Min: 1.63   Max: 19.17
Current: 5.96

1.63
19.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 68.00
BSPM's Price/Net Cash is ranked higher than
83% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BSPM: 68.00 )
BSPM' s 10-Year Price/Net Cash Range
Min: 0.8   Max: 101
Current: 68

0.8
101
Price/Net Current Asset Value 0.70
BSPM's Price/Net Current Asset Value is ranked higher than
100% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BSPM: 0.70 )
BSPM' s 10-Year Price/Net Current Asset Value Range
Min: 0.34   Max: 5.93
Current: 0.7

0.34
5.93
Price/Tangible Book 0.40
BSPM's Price/Tangible Book is ranked higher than
99% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. BSPM: 0.40 )
BSPM' s 10-Year Price/Tangible Book Range
Min: 0.19   Max: 3.49
Current: 0.4

0.19
3.49
Price/DCF (Projected) 0.20
BSPM's Price/DCF (Projected) is ranked higher than
100% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BSPM: 0.20 )
BSPM' s 10-Year Price/DCF (Projected) Range
Min: 0.08   Max: 0.48
Current: 0.2

0.08
0.48
Price/Median PS Value 1.00
BSPM's Price/Median PS Value is ranked higher than
82% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. BSPM: 1.00 )
BSPM' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 5.99
Current: 1

0.4
5.99
Price/Graham Number 0.80
BSPM's Price/Graham Number is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. BSPM: 0.80 )
BSPM' s 10-Year Price/Graham Number Range
Min: 0.12   Max: 1.24
Current: 0.8

0.12
1.24
Earnings Yield (Greenblatt) 3.70
BSPM's Earnings Yield (Greenblatt) is ranked higher than
67% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.00 vs. BSPM: 3.70 )
BSPM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 5250.8
Current: 3.7

1
5250.8
Forward Rate of Return (Yacktman) 36.42
BSPM's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. BSPM: 36.42 )
BSPM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 18.7   Max: 25.4
Current: 36.42

18.7
25.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:7BNA.Germany
Biostar Pharmaceuticals, Inc., is a Maryland corporation incorporated on March 27, 2007. It is a holding company that through its wholly-owned subsidiary Shaanxi Biostar Biotech, Ltd. and its variable interest entities Shaanxi Aoxing Pharmaceutical Co., Ltd., and Shaanxi Weinan Aoxing Pharmaceuticals, LLC develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the People's Republic of China. Its popular product is Xin Ao Xing Oleanolic Acid Capsule, an over-the- counter ("OTC") medicine for chronic hepatitis B. Its product line also includes five other OTC products, ten prescription-based pharmaceuticals, six nutriceuticals or health products and one medical device. The Company's products are derived from medicinal herbs that are either grown at its own facility or purchased from its suppliers. It has currently eight products under development to complement its existing product line. It has adopted international manufacturing standards and currently holds one patent, with two additional patents pending approval. The Company's products are currently being sold in over 25 provinces in the PRC through 25 distributors and an established network of more than 400 dedicated sales people. The Company's competitors includes, Wulanhaote Zhong Meng pharmaceutical Co., Ltd., Yang Ling Mai Di Sen Pharmaceutical Co., Ltd, Jiang Xi Ren He Pharmaceuticals, Inc; Hainan Asia Pharmaceuticals, Inc; Nan Yong An Pharmaceuticals, Inc; Hai Nan Min Hai Pharmaceuticals, Ltd; Shandong Bai Cao Pharmaceuticals, Ltd; Chang Chun Ren Min Pharmaceuticals, Ltd; Yun Nan Yu Xi City Wei He Pharmaceutical, Ltd; Shandong Phoenix Pharmaceuticals, Ltd; Wulanhaote Zhong Meng Pharmaceutical Co., Ltd; Yang Ling Mai Di Sen Pharmaceutical Co., Ltd; and other traditional Chinese medicine suppliers. The Company' operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protection bureaus in the PRC.
» More Articles for NAS:BSPM

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: ANADIGICS Inc., Biostar Pharmaceuticals Inc., Astrotech Corp. May 30 2011 

More From Other Websites
Nasdaq stocks posting largest volume increases Jul 25 2014
BIOSTAR PHARMACEUTICALS, INC. Financials May 23 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 15 2014
Biostar Pharmaceuticals, Inc. Announces First Quarter 2014 Financial Results May 15 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 31 2014
Biostar Pharmaceuticals, Inc. Announces Full Year 2013 Financial Results Mar 31 2014
Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of... Mar 10 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 10 2014
Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of... Mar 10 2014
China Biotech In Review: iKang Healthcare Planning $150 Million IPO In U.S. Mar 09 2014
Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop... Mar 06 2014
Biostar Pharmaceuticals to develop liver cancer drug with Chinese university Mar 06 2014
Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop... Mar 06 2014
Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating... Feb 20 2014
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 20 2014
Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating... Feb 20 2014
Biostar Held Its Strategic Development Seminar; Identified Development Planning for 2014 - 2016 Feb 16 2014
Biostar Held Its Strategic Development Seminar; Identified Development Planning for 2014 - 2016 Feb 14 2014
Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the... Jan 15 2014
Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the... Jan 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide